SlideShare a Scribd company logo
1 of 1
Download to read offline
REVIEW ON PHARMACOVIGILANCE
Aman. S. Maharaj, Abhishek. D. Nagdeve, Abhishek. A. Pachghare, Aasma. D. Shah (B Pharmacy 4th Year)
Guide By Miss. Smita Mankar (M. Pharm Pharmaceutic)
P R Patil Institute of Pharmacy, Talegaon (S.P.) Dist- Wardha 442202
ABSTRACT
Pharmacovigilance is an important and integral part of clinical
research. Pharmacovigilance is “defined as the pharmacological
science relating to the detection, assessment, understanding and
prevention of adverse effects, particularly long term and short term
adverse effects of medicines. This addresses what exactly is
pharmacovigilance. What do we know of its benefits and risks,
challenges and the future hold for pharmacovigilance in Indian
medicine. Here the main focus on the aims and role of
pharmacovigilance in medicines regulation and their Partners.
INTRODUCTION
WHO definition
Pharmacovigilance is a science and activities related to detection,
assessment, understanding and prevention of adverse effects or
any other medicine related problem.
As such, pharmacovigilance heavily focuses on adverse drug
reactions, Medication errors such as overdose, and misuse and
abuse of a drug as well as drug exposure during pregnancy and
breastfeeding, are also of interest, even without an adverse event,
because they may result in an adverse drug reaction.
Pharmacovigilance is still in its infancy in India and there exists
very limited knowledge about the discipline.
While major advancements of displine of pharmacovigilance have
taken place in the western countries not much has been achieved
in India. There is an immense need to understand the importance
of pharmacovigilance and how it impacts the life cycle of the
product. This will enable integration of good pharmacovigilance
practice in the process and procedures to help ensure regulatory
compliance and enhance clinical trials safety and post marketing
surveillance.
Pharmacovigilance is not new to India and has infact been going
on from 1998. When India decided to join the uppasla centre for
adverse event monitoring. The importance of pharmacovigilance
is withdrawls the regulatory agencies, media; consumers have
become more aware about the benefit and risks of medicines.
Presented at P. R. Patil Institute of Pharmacy , Talegaon (S.P.) during On 16 February 2023
GLOBAL PHARMACOVIGILANCE MARKET
SEGMENTATION
This report forecasts revenue growth at the global, regional, and country levels and
provides an analysis of the latest industry trends and opportunities in each of the sub-
segments from 2017 to 2030. For this study, Grand View Research has segmented the
global pharmacovigilance market report on the basis of service provider, product life
cycle, type, process flow, therapeutic area, end-use, and region:
• Service Provider Outlook (Revenue, USD Million, 2017 - 2030)
• In-house
• Contract Outsourcing
• Product Life Cycle Outlook (Revenue, USD Million, 2017 - 2030)
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV
• Type Outlook (Revenue, USD Million, 2017 - 2030)
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining
• Process Flow Outlook (Revenue, USD Million, 2017 - 2030)
• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Reviewing & Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review & Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System
• Therapeutic Area Outlook (Revenue, USD Million, 2017 - 2030)
• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others
• End-use Outlook (Revenue, USD Million, 2017 - 2030)
• Pharmaceuticals
• Biotechnology Companies
• Medical Device Manufacturers
• Others
• Regional Outlook (Revenue, USD Million, 2017 - 2030)
• North America
• U.S.
• Canada
• Europe
• U.K
• Germany
• France
• Italy
• Spain
• Russia
• Asia Pacific
• Japan
• China
• India
• Latin America
• Brazil
• Mexico
• Middle East and Africa
• South Africa
• Kingdom of Saudi Arabia
CONCLUSION
Pharmacovigilance looks at all available information to assess the
safety profile of a drug. Pharmacovigilance should also take the
benefit of the drug in account. Pharmacovigilance required for
systematically identifying and correlating drugs and side effects and
taking corrective actions.
REFERENCE
1. WHO, Pharmacovigilance: ensuring the safe use of medicines,
Geneva: WHO 2004.
2. WHO, Safety of medicines in public health programmes :
pharmacovigilance an essential tool, WHO, 2006.
3. WHO, Pharmacovigilance: ensuring the safe use of medicines,
Geneva: WHO 2002.
NATIONAL PROGRAMME PHARMACOVIGILANCE
Information about rare but serious adverse drug reactions, chronic toxicity, use in special
groups (e.g. pregnant women, children, elderly) and drug interactions is often incomplete or
not available. Certain adverse drug reactions may not be detected until a very large number of
people have received the medicine.
Pharmacovigilance is therefore one of the important post-marketing tools in ensuring the
safety of pharmaceutical and related health products.
• Assessing the risks and benefits of medicines in order to determine what action, if any, is
necessary to improve their safe use.
• Providing information to users to optimise safe and effective use of medicines.
• Monitoring the impact of any action taken.
PARTNERS IN PHARMACOVIGILANCE
The management of the risks associated with the use of medicines demands close and effective
collaboration between the key players in the pharmacovigilance. Sustained commitment to such
collaboration is vital if the future challenges in pharmacovigilance are to
be met, and if the discipline is to continue to develop and flourish.
Monitoring the safety of medicines: key partners
• Government
• Industry
• Hospitals and academia
• Medical and pharmaceutical associations
• Poisons and medicines information centres
• Health professionals
• Patients
• Consumers
• The media
• World Health Organization
AIMS OF PHARMACOVIGILANCE
Improve patient care and safety in relation to the use of medicines
and all medical and Paramedical interventions.
• Research the efficacy of drug and by monitoring the adverse
effects of drugs right from
the lab to the pharmacy and then on for many years.
• Pharmacovigilance keeps track of any drastic effects of drugs.
• Improve public health and safety in relation to the use of
medicines.
• Contribute to the assessment of benefit, harm, effectiveness and
risk of medicines,
encouraging their safe, rational and more effective (including
cost-effective)
use.
• Promote understanding, education and clinical training in
pharmacovigilance and its effective communication to the
public.
More information is generally needed about use in specific
populat ion groups, notably children, pregnant women and the
elderly, and about the efficacy and safety of chronic use,
especially in combination with other medicines. Experience has
shown that many adverse effects, interactions (i.e. with foods or
other medicines) and risk factors come to light only during the
years after the release of a medicine.
Medicine Adverse reaction
Reserpine Depression
Aminophenazone
(amidopyrine)
Agranulocytosis
Practolol Sclerosing peritonitis
Fluothane Hepatocellular hepatitis
Chloramphenicol Aplastic anaemia
Oral contraceptives Thromboembolism
Statins Rhabdomyolysis
Classical example of serious and unexpected adverse
reactions
NEED FOR PHARMACOVIGILANCE
Reason 1: Humanitarian concern - Insufficient evidence of safety from clinical trials Animal
experiments Phase 1-3 studies prior to marketing authorization.
Reason 2: Medicines are supposed to save lives Dying from a disease is sometimes
unavoidable; dying from a medicine is unacceptable.
Reason 3: ADR-related cost to the country exceeds the cost of the medications themselves.
Reason 4: Promoting rational use of medicines and adherence.
Reason 5: Ensuring public confidence.
Reason 6: Ethics, to know of something that is harmful to another person who does not know, and
not telling, is unethical.
ROLE OF PHARMACOVIGILANCE” IN MEDICINES
REGULATION
• Clinical trials;
• The safety of complementary and traditional medicines, vaccines and biological medicines;
• The development of lines of communication between all parties which have an interest in
medicine safety, ensuring that they are able to function efficiently and ethically, particularly at
times of crisis.
DIFFERENT PHARMACOVIGILANCE CENTER IN
INDIA

More Related Content

Similar to poster on PHARMACOVIGILANCE

introductiontopharmacoepidemiology-230613144442-c713d639.pdf
introductiontopharmacoepidemiology-230613144442-c713d639.pdfintroductiontopharmacoepidemiology-230613144442-c713d639.pdf
introductiontopharmacoepidemiology-230613144442-c713d639.pdf
Ogunsina1
 
Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01
Khadga Raj
 
PV UTILISATION, APPLICATION WHO PROGRAMME.pptx
PV UTILISATION, APPLICATION WHO PROGRAMME.pptxPV UTILISATION, APPLICATION WHO PROGRAMME.pptx
PV UTILISATION, APPLICATION WHO PROGRAMME.pptx
SAMYUKTHAKANDULA
 
pharmacovigilance pdf (1)
pharmacovigilance pdf (1)pharmacovigilance pdf (1)
pharmacovigilance pdf (1)
Prasad Bhat
 
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
Until ROI
 

Similar to poster on PHARMACOVIGILANCE (20)

Safety Reporting and Pharmacovigilance.pptx
Safety Reporting and Pharmacovigilance.pptxSafety Reporting and Pharmacovigilance.pptx
Safety Reporting and Pharmacovigilance.pptx
 
Pharmacoepidemiology (2)
Pharmacoepidemiology (2)Pharmacoepidemiology (2)
Pharmacoepidemiology (2)
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Outlining pharmacovigilance
Outlining pharmacovigilanceOutlining pharmacovigilance
Outlining pharmacovigilance
 
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
introductiontopharmacoepidemiology-230613144442-c713d639.pdf
introductiontopharmacoepidemiology-230613144442-c713d639.pdfintroductiontopharmacoepidemiology-230613144442-c713d639.pdf
introductiontopharmacoepidemiology-230613144442-c713d639.pdf
 
INTRODUCTION TO PHARMACOEPIDEMIOLOGY.pptx
INTRODUCTION TO PHARMACOEPIDEMIOLOGY.pptxINTRODUCTION TO PHARMACOEPIDEMIOLOGY.pptx
INTRODUCTION TO PHARMACOEPIDEMIOLOGY.pptx
 
Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
PV UTILISATION, APPLICATION WHO PROGRAMME.pptx
PV UTILISATION, APPLICATION WHO PROGRAMME.pptxPV UTILISATION, APPLICATION WHO PROGRAMME.pptx
PV UTILISATION, APPLICATION WHO PROGRAMME.pptx
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
 
pharmacovigilance pdf (1)
pharmacovigilance pdf (1)pharmacovigilance pdf (1)
pharmacovigilance pdf (1)
 
Pharmacovigilance pdf (1)
Pharmacovigilance pdf (1)Pharmacovigilance pdf (1)
Pharmacovigilance pdf (1)
 
1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx
 
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
 
postmarketing surviellance,,outsourcing of BA ,BE , CRO.
postmarketing surviellance,,outsourcing of BA ,BE , CRO. postmarketing surviellance,,outsourcing of BA ,BE , CRO.
postmarketing surviellance,,outsourcing of BA ,BE , CRO.
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Post Marketing Surveillance (Regulatory affairs).pptx
Post Marketing Surveillance (Regulatory affairs).pptxPost Marketing Surveillance (Regulatory affairs).pptx
Post Marketing Surveillance (Regulatory affairs).pptx
 
1482469439(ijcpcr)
1482469439(ijcpcr)1482469439(ijcpcr)
1482469439(ijcpcr)
 

Recently uploaded

Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 

Recently uploaded (20)

Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Plant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptxPlant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptx
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
latest AZ-104 Exam Questions and Answers
latest AZ-104 Exam Questions and Answerslatest AZ-104 Exam Questions and Answers
latest AZ-104 Exam Questions and Answers
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 

poster on PHARMACOVIGILANCE

  • 1. REVIEW ON PHARMACOVIGILANCE Aman. S. Maharaj, Abhishek. D. Nagdeve, Abhishek. A. Pachghare, Aasma. D. Shah (B Pharmacy 4th Year) Guide By Miss. Smita Mankar (M. Pharm Pharmaceutic) P R Patil Institute of Pharmacy, Talegaon (S.P.) Dist- Wardha 442202 ABSTRACT Pharmacovigilance is an important and integral part of clinical research. Pharmacovigilance is “defined as the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, particularly long term and short term adverse effects of medicines. This addresses what exactly is pharmacovigilance. What do we know of its benefits and risks, challenges and the future hold for pharmacovigilance in Indian medicine. Here the main focus on the aims and role of pharmacovigilance in medicines regulation and their Partners. INTRODUCTION WHO definition Pharmacovigilance is a science and activities related to detection, assessment, understanding and prevention of adverse effects or any other medicine related problem. As such, pharmacovigilance heavily focuses on adverse drug reactions, Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction. Pharmacovigilance is still in its infancy in India and there exists very limited knowledge about the discipline. While major advancements of displine of pharmacovigilance have taken place in the western countries not much has been achieved in India. There is an immense need to understand the importance of pharmacovigilance and how it impacts the life cycle of the product. This will enable integration of good pharmacovigilance practice in the process and procedures to help ensure regulatory compliance and enhance clinical trials safety and post marketing surveillance. Pharmacovigilance is not new to India and has infact been going on from 1998. When India decided to join the uppasla centre for adverse event monitoring. The importance of pharmacovigilance is withdrawls the regulatory agencies, media; consumers have become more aware about the benefit and risks of medicines. Presented at P. R. Patil Institute of Pharmacy , Talegaon (S.P.) during On 16 February 2023 GLOBAL PHARMACOVIGILANCE MARKET SEGMENTATION This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub- segments from 2017 to 2030. For this study, Grand View Research has segmented the global pharmacovigilance market report on the basis of service provider, product life cycle, type, process flow, therapeutic area, end-use, and region: • Service Provider Outlook (Revenue, USD Million, 2017 - 2030) • In-house • Contract Outsourcing • Product Life Cycle Outlook (Revenue, USD Million, 2017 - 2030) • Pre-clinical • Phase I • Phase II • Phase III • Phase IV • Type Outlook (Revenue, USD Million, 2017 - 2030) • Spontaneous Reporting • Intensified ADR Reporting • Targeted Spontaneous Reporting • Cohort Event Monitoring • EHR Mining • Process Flow Outlook (Revenue, USD Million, 2017 - 2030) • Case Data Management • Case Logging • Case Data Analysis • Medical Reviewing & Reporting • Signal Detection • Adverse Event Logging • Adverse Event Analysis • Adverse Event Review & Reporting • Risk Management System • Risk Evaluation System • Risk Mitigation System • Therapeutic Area Outlook (Revenue, USD Million, 2017 - 2030) • Oncology • Neurology • Cardiology • Respiratory Systems • Others • End-use Outlook (Revenue, USD Million, 2017 - 2030) • Pharmaceuticals • Biotechnology Companies • Medical Device Manufacturers • Others • Regional Outlook (Revenue, USD Million, 2017 - 2030) • North America • U.S. • Canada • Europe • U.K • Germany • France • Italy • Spain • Russia • Asia Pacific • Japan • China • India • Latin America • Brazil • Mexico • Middle East and Africa • South Africa • Kingdom of Saudi Arabia CONCLUSION Pharmacovigilance looks at all available information to assess the safety profile of a drug. Pharmacovigilance should also take the benefit of the drug in account. Pharmacovigilance required for systematically identifying and correlating drugs and side effects and taking corrective actions. REFERENCE 1. WHO, Pharmacovigilance: ensuring the safe use of medicines, Geneva: WHO 2004. 2. WHO, Safety of medicines in public health programmes : pharmacovigilance an essential tool, WHO, 2006. 3. WHO, Pharmacovigilance: ensuring the safe use of medicines, Geneva: WHO 2002. NATIONAL PROGRAMME PHARMACOVIGILANCE Information about rare but serious adverse drug reactions, chronic toxicity, use in special groups (e.g. pregnant women, children, elderly) and drug interactions is often incomplete or not available. Certain adverse drug reactions may not be detected until a very large number of people have received the medicine. Pharmacovigilance is therefore one of the important post-marketing tools in ensuring the safety of pharmaceutical and related health products. • Assessing the risks and benefits of medicines in order to determine what action, if any, is necessary to improve their safe use. • Providing information to users to optimise safe and effective use of medicines. • Monitoring the impact of any action taken. PARTNERS IN PHARMACOVIGILANCE The management of the risks associated with the use of medicines demands close and effective collaboration between the key players in the pharmacovigilance. Sustained commitment to such collaboration is vital if the future challenges in pharmacovigilance are to be met, and if the discipline is to continue to develop and flourish. Monitoring the safety of medicines: key partners • Government • Industry • Hospitals and academia • Medical and pharmaceutical associations • Poisons and medicines information centres • Health professionals • Patients • Consumers • The media • World Health Organization AIMS OF PHARMACOVIGILANCE Improve patient care and safety in relation to the use of medicines and all medical and Paramedical interventions. • Research the efficacy of drug and by monitoring the adverse effects of drugs right from the lab to the pharmacy and then on for many years. • Pharmacovigilance keeps track of any drastic effects of drugs. • Improve public health and safety in relation to the use of medicines. • Contribute to the assessment of benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and more effective (including cost-effective) use. • Promote understanding, education and clinical training in pharmacovigilance and its effective communication to the public. More information is generally needed about use in specific populat ion groups, notably children, pregnant women and the elderly, and about the efficacy and safety of chronic use, especially in combination with other medicines. Experience has shown that many adverse effects, interactions (i.e. with foods or other medicines) and risk factors come to light only during the years after the release of a medicine. Medicine Adverse reaction Reserpine Depression Aminophenazone (amidopyrine) Agranulocytosis Practolol Sclerosing peritonitis Fluothane Hepatocellular hepatitis Chloramphenicol Aplastic anaemia Oral contraceptives Thromboembolism Statins Rhabdomyolysis Classical example of serious and unexpected adverse reactions NEED FOR PHARMACOVIGILANCE Reason 1: Humanitarian concern - Insufficient evidence of safety from clinical trials Animal experiments Phase 1-3 studies prior to marketing authorization. Reason 2: Medicines are supposed to save lives Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. Reason 3: ADR-related cost to the country exceeds the cost of the medications themselves. Reason 4: Promoting rational use of medicines and adherence. Reason 5: Ensuring public confidence. Reason 6: Ethics, to know of something that is harmful to another person who does not know, and not telling, is unethical. ROLE OF PHARMACOVIGILANCE” IN MEDICINES REGULATION • Clinical trials; • The safety of complementary and traditional medicines, vaccines and biological medicines; • The development of lines of communication between all parties which have an interest in medicine safety, ensuring that they are able to function efficiently and ethically, particularly at times of crisis. DIFFERENT PHARMACOVIGILANCE CENTER IN INDIA